Dr. Stuart Wong, MD
Medical Oncology (Medical Oncology Physician)
9200 W Wisconsin Ave, Neoplastic Diseases
Milwaukee, WI 53226
Who else practices at this address →
Milwaukee County includes primary care (32% of residents) and mental health (34% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 7
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 96
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
WI license 33593
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Froedtert Memorial Lutheran Hospital Milwaukee, WI
- Waukesha Memorial Hospital Waukesha, WI
- Community Memorial Hospital Menomonee Falls, WI
Medical groups
- The Medical College of Wisconsin Inc (2,115 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 96
- Services billed
- 347
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 173 | 63 |
| Established patient office or other outpatient visit, 40-54 minutes | 37 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 30 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Milwaukee, WI | 43 |
| Dexamethasone Other prescribers in Milwaukee, WI | 19 |
| Olanzapine Other prescribers in Milwaukee, WI | 18 |
| Tafinlar (dabrafenib mesylate) | 12 |
| Mekinist (trametinib dimethyl sulfoxide) | 12 |
| Gilotrif (afatinib dimaleate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $2,556,537 in research payments for these studies, mostly to the institutions running them.
- Study name#keystroke# a randomized phase ii study of pembrolizumab keytruda plus stereotactic re-irradiation versus sbrt alone for locoregionally recurrent or second primary head and neck carcinoma
Merck Sharp & Dohme LLC - Study name#keystroke# a randomized phase ii study of pembrolizumab keytruda plus stereotactic re-irradiation versus sbrt alone for locoregionally recurrent or second primary head and neck carcinoma
Merck Sharp & Dohme LLC - Keystroke: a randomized phase ii study of pembrolizumab (keytruda®) plus stereotactic re-irradiation versus sbrt alone for locoregionally recurrent or second primary head and neck carcinoma
Merck Sharp & Dohme LLC - A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04626635 - A phase 2, randomized, open-label, platform study using a master proto
GlaxoSmithKline, LLC. - A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib …
Merck Sharp & Dohme LLC - RTOG1
Coherus Oncology, Inc. - A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Recruiting · NCT06064877 - Head And Neck Cancer Squamous Cell Carcinoma
Aveo Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.